Evidence map›Paper›PMID 42812996›Full record

ReviewACS central science2026

Advancing Drug Discovery through Academia-Industry Collaborations: Lessons from Merck Discovery Chemistry Partnerships.

Beryl X Li, Dipannita Kalyani

Abstract readReview
In one paragraph

Review in ACS central science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Beryl X LiDiscovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States.
Dipannita KalyaniDiscovery Chemistry, Merck & Co., Inc., Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0003-4349-8016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Academia-industry partnerships are an important driver of innovation in drug discovery, and their success depends on intentional problem selection, effective resource sharing, and robust communication during project execution. This outlook highlights select Merck Sharp & Dohme Discovery Chemistry (MSD DC) collaborations reported over the past five years to illustrate principles that underpin productive academia-industry partnerships. Through representative case studies in synthesis collaborations, we illustrate two complementary collaboration strategies: targeted development of synthetic methods that address key medicinal chemistry bottlenecks, and capability-building efforts that enable technology transfer to accelerate drug discovery. We also highlight a few nonsynthetic collaborations by MSD DC in computational chemistry, structure elucidation, and chemical biology subfields, underscoring the cross-functional impact of these efforts on drug discovery. Beyond scientific advances, these collaborations also provide meaningful training and professional development opportunities for the next generation of chemists.

Identifiers

PMID42812996
PMCPMC13621362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.